This list is an analysis based on recent market events. It's not an investment recommendation.
PharmAust Limited, a clinical stage biotechnology company, develops therapeutics for neurodegenerative diseases in Switzerland, Australia, the United States, and internationally. The company develops drug discovery intellectual property for the treatment of various cancers and neurological diseases. Its lead candidate is Monepantel (MPL), a small molecule drug which is in Phase II clinical trials for the treatment of amyotrophic lateral sclerosis, as well as to treat other neurodegenerative diseases, such as Alzheimer's and Parkinson's disease. PharmAust Limited was incorporated in 2000 and is based in Melbourne, Australia.
Show more...
FAQ
What is Pharmaust stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Stuttgart exchange Pharmaust stocks are traded under the ticker ECQ.STU.
What is Pharmaust revenue for the last year?▼
Pharmaust revenue for the last year amounts to 0 EUR.
What is Pharmaust net income for the last year?▼
ECQ.STU net income for the last year is -9.55M EUR.
In which sector is Pharmaust located?▼
Pharmaust operates in the Health & Wellness sector.
When did Pharmaust complete a stock split?▼
Pharmaust has not had any recent stock splits.
Where is Pharmaust headquartered?▼
Pharmaust is headquartered in Melbourne, Australia.